FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced positive ...

Already half the world’s population is thought to have it, but new research suggests there’s been a 53 per cent increase in a particular form, seborrheic dermatitis – an inflammatory skin condition ...

Already half the world’s population is thought to have it, but new research suggests there’s been a 53 per cent increase in a particular form, seborrheic dermatitis – an inflammatory skin condition ...

Researchers at The Jackson Laboratory (JAX), in collaboration with the Massachusetts Institute of Technology (MIT), have ...

A DAD is in a desperate race against time after being given a devastating cancer diagnosis – but told he wasn’t eligible for ...

Researchers at The Jackson Laboratory (JAX), in collaboration with the Massachusetts Institute of Technology (MIT), have ...

Among patients with moderate to severe atopic dermatitis, APG777 produced significant reductions in disease severity at 16 weeks.